ERBB2 and breast carcinoma: The prospective randomized MAINSTREAM trial NCT05465031 will clarify if the higher tolerated dose of Sacubitril/Valsartan can prevent cardiotoxicity in patients with breast cancer undergoing anthracyclines+/-anti-HER2 regimens [107].